ClinicalTrials.gg
CompletedNCT06729268Updated Dec 31, 2024

Fluid Responsiveness Tests in Critically Ill Patients During Admission to the Intensive Care Unit

An observational study in Shock Circulatory, Heart Failure and Hypovolemia, sponsored by Uniwersytecki Szpital Kliniczny w Opolu. Completed at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by Uniwersytecki Szpital Kliniczny w Opolu · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
389
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Shock with a site in Poland — none open to participants now, none under way, none of them phase 3. Shock · Poland.

Started
2023
the only one that year
Observational
6 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
2 of 10
Uniwersytecki Szpital Kliniczny w Opolu

Among the 10 studies in Shock with a site in Poland, this one is the only one that started in 2023, is one of 6 observational ones, and was the 8th registered.

Shock

487 studies on the registry are indexed under Shock; 107 are open to participants now.

Browse Shock studies →

Open to participants now

None of the 10 studies in Shock with a site in Poland is open now. The open studies under Shock, anywhere →

Who these studies take

Of the 68 Shock studies recruiting now, 52 (76%) set no upper age limit and 11 (16%) stop at 75 or younger; 9 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Shock with a site in Poland as a file.
02

Study summary

The goal of this observational study is to investigate the prevalence of conditions allowing the performance fluid responsiveness tests in critically ill patients during admission to the intensive care unit.

Read the detailed description

Patients admitted to the intensive care unit are very often hemodynamically unstable. In these cases fluid responsiveness tests should be performed to assess whether the patient would benefit from the fluid administration.

However, fluid responsiveness tests have many limitations including lack of spontaneous breathing, necessity of invasive mechanical ventilation with tidal volume of > 8 mL/kg ideal body weight, regular hearth rhythm, and lack of abdominal hypertension.

In the study, the investigators evaluated the prevalence of conditions enabling the performance fluid responsiveness tests in patients admitted to the intensive care unit. An assessment was performed within the six hours after admission to the intensive care unit. Evaluation was based on transthoracic echocardiography, clinical examination of the patients, and data derived from anamnesis.

The following fluid responsiveness tests were included into assessment: passive leg raising test, end-expiratory occlusion test, pulse pressure variation, stroke volume variation, velocity time integral variation in left ventricle output track, tidal volume challenge, inferior vena cava diameter variation, and superior vena cava diameter variation.

The aim of the study was to assess how many patients have the conditions allowing performance fluid responsiveness tests during admission to the intensive care unit.

03

Conditions studied

  • Shock Circulatory
  • Heart Failure
  • Hypovolemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients admitted to the intensive care unit

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult patients admitted to the intensive care unit

Exclusion criteria

Exclusion Criteria:

  1. Age under 18
  2. The researcher unavailable in the intensive care unit
  3. Patient assessment cannot be completed within the first six hours after admission to the ICU
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
389 participants (actual)
Patient registry
No

Groups and cohorts

  • Patients treated in the intensive care unit

    Patients treated in the intensive care unit during the first six hours after admission.

06

What researchers measure

Primary outcomes

  1. To assess the prevalence of conditions allowing the performance fluid responsiveness tests during admission to the intensive care unit.

    The primary aim of the study is to assess the prevalence of conditions allowing the performance fluid responsiveness tests during admission to the intensive care unit.

    Time frame: Six hours after admission to the intensive care unit

Secondary outcomes

  1. To assess which fluid responsiveness test based on heart-lung interactions can be applied most often during admission to the intensive care unit

    The secondary aim of the study is to assess which fluid responsiveness test based on heart-lung interaction can be applied most often during admission to the intensive care unit

    Time frame: Six hours after admission to the intensive care unit

  2. To assess the percentage of patients in shock whom fluid responsiveness tests can be performed during admission to the intensive care unit

    Secondary aim include an assessment the percentage of patients in shock whom fluid responsiveness tests can be performed during admission to the intensive care unit.

    Time frame: Six hours from the admission to the intensive care unit.

07

Study locations

1 site
  • Department of Anesthesiology and Intensive Care, Uniwersytecki Szpital Kliniczny w Opolu
    Opole, 45-401, Poland
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2023 to primary completion in May 2024, 13 months.

Of 121 non-industry observational studies under Shock, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 52. This study's 13 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 11 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2024
First posted
Dec 11, 2024
StartActual
Apr 3, 2023
Primary completionActual
May 27, 2024
CompletionActual
May 27, 2024
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06729268
Lead sponsor
Uniwersytecki Szpital Kliniczny w Opolu
Responsible party
Ryszard Gawda (Principal Investigator, Uniwersytecki Szpital Kliniczny w Opolu) — Principal investigator
First posted
Dec 11, 2024
Start date
Apr 3, 2023
Primary completion
May 27, 2024
Completion
May 27, 2024
Last update
Dec 31, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion